Fundraising Fox
AeroRx Therapeutics
La Jolla, US · Founded 2024 · 3 known investors
Find your way into AeroRx Therapeutics
Sign up to see every warm intro you have to AeroRx Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AeroRx Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers. Its pipeline targets high-risk respiratory patients, including older individuals and those with dexterity limitations who benefit from nebulized delivery.
Founders & leadership
AeroRx Therapeutics was founded in 2024 by Ahmet Tutuncu.
Board
Investors · 3
How we know: Avalon BioVentures's portfolio page · funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10.4M disclosed across 1 round · 2025
▶$10.4MraisedOct 2025 · 17 investors · Other Health CareRule 506(b)
- Ahmet Tutuncu, M.D., Ph.D.Executive Officer, Director
- Tighe ReardonExecutive Officer
- Heather Preston, M.D.Director
- Jay B. Lichter, Ph.D.Director
- John Stuart Patton, Ph.D.Director
- Sanford Madigan, Ph.D.Director
- Offering amount
- $20.8M
- Amount sold
- $10.4M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does AeroRx Therapeutics do?
- AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers. Its pipeline targets high-risk respiratory patients, including older individuals and those with dexterity limitations who benefit from nebulized delivery.
- Who founded AeroRx Therapeutics?
- AeroRx Therapeutics was founded by Ahmet Tutuncu in 2024.
- Who are AeroRx Therapeutics's investors?
- AeroRx Therapeutics's investors include Avalon BioVentures, Alexandria, Correlation Ventures.
- How much funding has AeroRx Therapeutics raised?
- AeroRx Therapeutics has disclosed $10.4M raised across 1 round.
- Where is AeroRx Therapeutics headquartered?
- AeroRx Therapeutics is headquartered in La Jolla, US.